1. Home
  2. FGI vs PHGE Comparison

FGI vs PHGE Comparison

Compare FGI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

HOLD

Current Price

$8.49

Market Cap

7.5M

Sector

Industrials

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.77

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
PHGE
Founded
1987
2015
Country
United States
United States
Employees
420
57
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FGI
PHGE
Price
$8.49
$0.77
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
303.0K
286.3K
Earning Date
04-09-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.38
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.25
52 Week High
$12.62
$8.50

Technical Indicators

Market Signals
Indicator
FGI
PHGE
Relative Strength Index (RSI) 60.14 23.00
Support Level $4.36 $0.43
Resistance Level $11.84 $2.35
Average True Range (ATR) 2.21 0.22
MACD 0.06 -0.01
Stochastic Oscillator 55.27 7.39

Price Performance

Historical Comparison
FGI
PHGE

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: